Bullous Pemphigoid Diagnosis and Treatment

Disease Characteristics

• Bullous pemphigoid is the most common autoimmune subepidermal blistering disease affecting primarily elderly patients, characterized by tense bullae and intense pruritus, with significant morbidity and mortality risk 1
• The disease has a significant association with neurological disorders including dementia, Parkinson's disease, and stroke 1, 2

Clinical Presentation

• Classic presentation includes generalized or localized tense bullae on erythematous or normal-appearing skin, typically with severe pruritus 1, 3
• Non-bullous variants, occurring in up to 20% of cases, may present with excoriations, prurigo-like lesions, eczematous patches, urticarial plaques, or dyshidrosiform lesions without visible blisters 1, 3

Diagnostic Approach

• The British Journal of Dermatology recommends a diagnostic workup that includes confirming BP diagnosis, identifying risk factors and comorbidities, assessing disease extent and severity, evaluating general condition, and reviewing medication history 1
• The diagnostic workup should be supervised by a dermatologist experienced in autoimmune blistering diseases, ideally affiliated with or consulting a referral center 1, 3

Treatment Strategy

• The American Academy of Dermatology recommends superpotent topical corticosteroids as the first-line treatment for all disease severities, providing superior disease control with significantly lower mortality compared to systemic corticosteroids 4
• The treatment regimen includes applying clobetasol propionate directly to lesions only for localized disease, to the whole body except face for mild widespread disease, and to the entire body except face for generalized disease, with a standard dose of 20g/day 4
• The British Journal of Dermatology recommends beginning tapering after 15 days once disease control is achieved, and reducing to maintenance therapy of 10g once weekly after 4 months 4

Alternative Treatments

• Doxycycline 200 mg/day combined with nicotinamide represents a safer alternative to systemic corticosteroids, particularly for patients at high risk for steroid complications, with a response rate of 73.8% and reduced mortality 4
• Azathioprine combined with prednisone allows reduction of steroid dose by approximately 45%, serving as a steroid-sparing agent 4

Monitoring and Follow-Up

• Regular monitoring is essential to assess disease activity, adjust treatment, and detect complications early, with visits scheduled every 2 weeks for the first 3 months, monthly for months 4-6, and every 2 months after 6 months 4
• Laboratory monitoring should include assessing disease activity at each visit, considering anti-BP180 IgG ELISA at days 0, 60, and 150, and monitoring for relapse indicators such as BP180 ELISA >27 U/mL or positive DIF 4

Special Considerations

• Approximately 50% of drug-induced BP cases persist after drug withdrawal, requiring conventional BP treatment 2
• Positive DIF or elevated BP180 ELISA indicates higher relapse risk 4
• The American Academy of Dermatology recommends considering doxycycline for high-risk patients, such as elderly patients with multiple comorbidities, due to its superior safety profile despite slightly lower efficacy 4

Diagnosis and Management of Bullous Pemphigoid and Scabies‑Mimicking Bullous Eruptions

Clinical Presentation and Epidemiology

• Typical bullous pemphigoid presents with tense bullae on erythematous or normal‑appearing skin, severe itching, and mainly affects patients older than 70 years. 5
• Approximately 20 % of bullous pemphigoid cases lack visible blisters and manifest as refractory pruritus, excoriations, prurigo‑like or eczematous lesions, urticarial plaques, or dyshidrosiform eruptions in elderly individuals. 6
• Lesion distribution is usually generalized or localized, sparing the head and neck, and mucosal involvement is uncommon. 5

Diagnostic Tests

• Direct immunofluorescence (DIF) of perilesional skin is mandatory for confirming bullous pemphigoid; it shows linear IgG and/or C3 deposition along the dermo‑epidermal junction. 5
• Skin‑biopsy histopathology from a fresh bulla typically reveals a subepidermal blister with eosinophils and/or neutrophils, plus a dermal eosinophilic infiltrate that may marginalize along the dermo‑epidermal junction. 5
• Serologic assessment (ELISA for anti‑BP180/BP230 antibodies or indirect immunofluorescence on salt‑split skin) demonstrates IgG binding to the epidermal side, supporting the diagnosis of bullous pemphigoid. 5

Diagnostic Scenarios

• Pure bullous pemphigoid is identified by a negative scabies skin‑scraping result combined with a positive DIF, and should prompt review of recent exposure to known trigger drugs (e.g., diuretics, psycholeptics). 5

Drug‑Induced Bullous Pemphigoid

• Diuretics, psycholeptic agents (such as phenothiazines), and immune checkpoint inhibitors are recognized triggers for bullous pemphigoid. 5
• About half of drug‑induced bullous pemphigoid cases persist after discontinuation of the offending medication, necessitating conventional bullous pemphigoid therapy. 5

Evidence‑Based Management of Bullous Pemphigoid in High‑Risk Elderly Patients

Prognostic Factors and Mortality

• In elderly patients with multiple comorbidities, treatment with high‑dose systemic corticosteroids (prednisone > 40 mg/day) is associated with a markedly increased mortality risk compared with topical therapy. 7, 8, 9
• Advanced age at disease onset and a frail general condition are independent poor‑prognostic factors; during the active phase, mortality is roughly twice that of the age‑matched general elderly population. 7, 8
• The coexistence of dementia, diabetes, and cardiovascular disease markedly raises the likelihood of steroid‑induced complications such as hyperglycaemia, infections, cardiac events, and worsening cognition. 9

Steroid‑Sparing Strategies

Azathioprine

• Prior to initiating azathioprine, assessment of thiopurine‑methyltransferase (TPMT) activity is recommended to prevent severe myelosuppression. 7
• A typical azathioprine regimen of 1–2.5 mg/kg/day, combined with low‑dose prednisone, yields a steroid‑sparing effect that becomes evident after 4–6 weeks. 7

Systemic Corticosteroid Dosing Recommendations

• When systemic corticosteroids are unavoidable, the initial dose should be the lowest effective amount: 0.3 mg/kg/day for moderate disease or up to 0.5 mg/kg/day for severe involvement. Doses exceeding 0.75 mg/kg/day are linked to significantly higher mortality in this population. 9
• Dosing in the range of 0.75–1.0 mg/kg/day can achieve disease control in 60–90 % of patients within 1–4 weeks, but the associated mortality risk makes this approach a last‑resort option. 8, 9

Safety Pitfalls

• Initiating high‑dose systemic corticosteroids (>0.75 mg/kg/day) in elderly patients with multiple comorbidities should be avoided because the mortality risk outweighs any potential benefit. 7, 8, 9
• Escalating therapy in response to an isolated “occasional blister” during the maintenance phase leads to overtreatment and unnecessary toxicity; such changes are not recommended. 10
• Clinicians should remember that bullous pemphigoid is typically self‑limiting and often remits within five years; treatment goals should focus on symptom control with minimal toxicity rather than complete disease eradication. 10

Neurological Associations

• A well‑established link exists between bullous pemphigoid and neurological disorders, including dementia; the presence of dementia may be related to, or exacerbated by, the underlying autoimmune skin disease. 11